Nature publishes study on melanoma addiction to the long non-coding RNA SAMMSON, providing solid proof-of-concept for Biogazelle’s lncRNA targeting anti-cancer platform

on March 24, 2016

The 'Survival Associated Mitochondrial Melanoma Specific ONcogenic RNA' is a long non-coding RNA that is specifically expressed in malignant melanoma cells, and not in other normal human cells or other cancer types. Using antisense mediated RNA targeting therapy, Leucci et al. selectively kill melanoma cells in vitro and in vivo xenograft mouse models. Biogazelle’s therapeutic programs build on similar synergy between the specific expression pattern of a given lncRNA, and the self-delivering capacity and target-specificity of nucleic acid-based drugs, to develop effective anti-cancer therapies with minimal side effects and toxicity. Biogazelle has proprietary data and knowledge to prioritize candidate therapeutic RNA targets in liver, colon and lung cancer. Hundreds of candidate therapeutic lncRNA targets are currently being evaluated in large-scale in vitro screenings.